Source: Yale News, 2 April 2026
A Yale team screened 774 existing medicines in zebrafish carrying changes in two genes linked to autism, SCN2A and DYRK1A. One compound, levocarnitine, reversed some of the altered behaviour in the fish and improved activity in human nerve cells grown in the laboratory with the same gene changes. This is early laboratory research published in PNAS. It has not been tested in people and is not a treatment for autism.
Read the full story at Yale News
This is a short report on news published elsewhere, written by the Australian Autism ADHD Foundation. Including it here is not an endorsement. For advice about your own situation, please speak with a qualified health professional.